Clinical Trial Update: An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

This document reports the results of a Phase 3 open-label study comparing Insulin VIAject with Regular Human Insulin in patients with Type 1 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin VIAject (insulin)
• Regular human insulin (human insulin (regular))

Snippet

Sponsor: Biodel | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED